The FDA has approved the first prescription, at-home neuromodulation therapy for individuals with major depressive disorder ...
Medical Device Network on MSN
Abbott touts neuromodulation portfolio’s long-term benefits
Abbott’s five-year data highlighted neuromodulation therapies’ role in reducing healthcare and patient burdens associated ...
At booth #115, Integer will spotlight its latest advancements in neuromodulation and next-generation miniaturized active implantable medical devices (AIMDs). These innovations are designed to ...
The wearable device delivers electrical impulses through a headset that can be administered by the patient at home under ...
Abbott’s neuromodulation systems can significantly reduce pain-related healthcare visits for people living with chronic pain, according to five-year data.
Peer-reviewed Phase 2 Results Inform Ongoing Phase 3/Pivotal Trial of Celeste® in Parkinson’s Disease The Phase 2 study ...
CVRx’s stock has risen nearly 20% after the company revealed that its heart failure device is set to be investigated in an ...
ReShape Lifesciences has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application on a new Diabetes Neuromodulation system utilizing its vagal nerve block ...
Resonetics said buying Resolution Medical would expand its capabilities in neuromodulation, structural heart and ...
Resonetics announced today that it has signed an agreement to acquire Resolution Medical, a leading provider of integrated design and manufacturing solutions for complex medical devices. Resolution ...
Given the growing interest in non-invasive neuromodulation devices for the central nervous system, the Forum on Neuroscience and Nervous System Disorders hosted a public workshop on March 2-3, 2015 to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results